Department of Medical Laboratories, Faculty of Allied Health Sciences, Hashemite University, Zarqa, Jordan.
J Breast Cancer. 2012 Jun;15(2):157-61. doi: 10.4048/jbc.2012.15.2.157. Epub 2012 Jun 28.
Although the etiology of breast cancer is multifactorial, oxidative stress plays an important role in carcinogenesis. In this study, manganese superoxide dismutase (MnSOD) gene polymorphism and activity were evaluated in benign and breast cancer tissue.
One hundred and one females were enrolled in this study, 65 who were histopathologically diagnosed with breast cancer and 46 who were benign patients. MnSOD enzyme activity was determined using an indirect competitive inhibition assay and MnSOD gene polymorphism using poly merase chain reaction and agarose gel electrophoresis.
MnSOD enzymatic activity (79.83±42.14) was lower in breast cancer tissue compared to benign tumors (236.18±46.37). At the same time, MnSOD enzymatic activity among Ala/Val patients was significantly lower in breast cancer tissue (39.19±7.33) than in Val/Val malignant breast tumors tissue (96.9±22.9). MnSOD enzymatic activity was significantly lower in Val/Val cancer tissue (96.9±22.9) than in benign tissue (255.44±42.7).
Breast cancer tumors contain less MnSOD than benign breast samples. Patients with Ala/Val polymorphism had reduced MnSOD activity compared to patients with Val/Val breast cancer. Ala/Val gene polymorphism may be a risk factor associated with more advanced breast cancer stage. MnSOD gene polymorphism Ala/Val may be a risk factor associated with more advanced breast cancer stage, and reduction of MnSOD activity may be a mechanism of the progression of benign to malignant tumors. Further investigations are needed to evaluate the role of MnSOD in breast cancer progression.
尽管乳腺癌的病因是多因素的,但氧化应激在致癌作用中起着重要作用。在这项研究中,评估了锰超氧化物歧化酶(MnSOD)基因多态性和活性在良性和乳腺癌组织中的变化。
本研究纳入了 101 名女性,其中 65 名经组织病理学诊断为乳腺癌,46 名为良性肿瘤患者。使用间接竞争抑制测定法测定 MnSOD 酶活性,用聚合酶链反应和琼脂糖凝胶电泳法测定 MnSOD 基因多态性。
与良性肿瘤相比,乳腺癌组织中的 MnSOD 酶活性(79.83±42.14)较低。同时,Ala/Val 患者的 MnSOD 酶活性在乳腺癌组织中(39.19±7.33)明显低于 Val/Val 恶性乳腺癌组织中(96.9±22.9)。乳腺癌组织中的 MnSOD 酶活性明显低于良性组织中的(255.44±42.7)。
乳腺癌组织中 MnSOD 的含量低于良性乳腺样本。与 Val/Val 乳腺癌患者相比,Ala/Val 多态性患者的 MnSOD 活性降低。Ala/Val 基因多态性可能是与更晚期乳腺癌相关的危险因素。MnSOD 基因多态性 Ala/Val 可能是与更晚期乳腺癌相关的危险因素,MnSOD 活性降低可能是良性肿瘤向恶性肿瘤发展的机制。需要进一步的研究来评估 MnSOD 在乳腺癌进展中的作用。